BERKELEY, Calif., July 24, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, today announced the start of its Phase 2a clinical trial to evaluate XOMA 629, a topical gel formulation of an antimicrobial drug candidate, as a treatment for impetigo. Impetigo is a superficial skin infection caused by bacteria, and is more common in children and young adults. It is estimated to affect one million people in the U.S. annually.
